MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific Total Current Liabilities 2011-2026 | TMO
Annual Total Current Liabilities Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.2 B | 13.3 B | 14 B | 17 B | 13.4 B | 10.3 B | 6.2 B | 6.15 B | 7.05 B | 4.87 B | 4.15 B | 5.35 B | 3.13 B | 2.09 B | 3.11 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17 B | 2.09 B | 8.36 B |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 203.83 | 0.02 % | $ 22.6 B | USA |
 |
Celcuity
CELC
|
44.2 M | $ 89.49 | 1.42 % | $ 4.18 B | USA |
 |
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
3.54 M | $ 4.7 | -3.69 % | $ 6.25 M | USA |
 |
Fulgent Genetics
FLGT
|
85 M | $ 18.78 | -0.79 % | $ 578 M | USA |
 |
Castle Biosciences
CSTL
|
68.7 M | $ 21.01 | -0.33 % | $ 609 M | USA |
 |
Aspira Women's Health
AWH
|
3.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
31.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
3.2 B | $ 149.92 | 3.69 % | $ 11.8 B |  Irlanda |
 |
Illumina
ILMN
|
1.58 B | $ 166.21 | 2.3 % | $ 25.8 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
303 M | $ 130.9 | 0.15 % | $ 16.4 B | USA |
 |
CareDx, Inc
CDNA
|
89.8 M | $ 23.66 | 0.85 % | $ 1.26 B | USA |
 |
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.05 M | - | - | $ 9.42 M |  Israel |
 |
Interpace Biosciences
IDXG
|
5.1 M | $ 1.65 | -6.41 % | $ 7.3 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
333 M | $ 104.32 | 4.07 % | $ 7.04 B | USA |
 |
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.35 | -1.46 % | $ 405 M | USA |
 |
Charles River Laboratories International
CRL
|
1.12 B | $ 188.06 | 0.95 % | $ 9.32 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
1.34 B | $ 475.07 | 2.01 % | $ 13.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
641 M | - | - | $ 19.8 B | USA |
 |
Mettler-Toledo International
MTD
|
1.2 B | $ 1 141.25 | 0.73 % | $ 23.5 B |  Schweiz |
 |
NeoGenomics
NEO
|
88.3 M | $ 11.47 | 1.68 % | $ 1.47 B | USA |
 |
Myriad Genetics
MYGN
|
134 M | $ 4.63 | 4.51 % | $ 429 M | USA |
 |
National Research Corporation
NRC
|
36.6 M | $ 18.79 | -11.7 % | $ 421 M | USA |
 |
Natera
NTRA
|
441 M | $ 219.23 | 1.26 % | $ 30 B | USA |
 |
Personalis
PSNL
|
39.6 M | $ 9.42 | -1.98 % | $ 841 M | USA |
 |
Senseonics Holdings
SENS
|
24.3 M | $ 7.33 | 0.41 % | $ 306 M | USA |
 |
Twist Bioscience Corporation
TWST
|
91.4 M | $ 74.05 | 9.27 % | $ 4.43 B | USA |
 |
QIAGEN N.V.
QGEN
|
512 M | - | - | $ 10.6 B |  Niderland |
 |
Soleno Therapeutics
SLNO
|
61.4 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
1.74 M | $ 2.09 | 3.47 % | $ 4.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 265.27 | -1.26 % | $ 22.1 B | USA |
 |
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
174 M | $ 9.24 | 0.82 % | $ 2 B | USA |
 |
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | USA |